Ibsa Institut Biochimique Sa Patent-Cliff Exposure & CMS Drug Spending Portfolio
Ibsa Institut Biochimique Sa (US): 5 reconciled FDA prescription therapies, $39.4M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 5 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2033-01-01 |
| 2024 CMS Total Public Spend | $39.4M |
| 2024 Medicare Part D Spend | $28.8M |
| 2024 Medicaid Spend | $10.7M |
| California HCAI SB 17 Filings | 1 WAC filings (max 24.2% 2-yr change) |